Clinical trial
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790
Study timeline
Study start (actual)2020-08-01Date precision: day
Registry last updated2025-02-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosis, Relapsing-Remittingunresolved
Interventions
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
Sponsors & collaborators
Johns Hopkins Universitylead sponsor
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04261790 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.